Colo-205 mice were treated at doses of 0.05, 0.2, and 0.4 μCi. Reduction of tumor volume was seen in all doses. LNCap and A549 showed similar results after a single dose. DNA double-strand breaks were studied with yH2AX. Phase, I trials with FPI-1434,4 will begin soon.
Presented by: Eric Burak, PhD, Fusion Pharmaceuticals, Hamilton, Ontario, Canada
Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10) April 1 - April 4, 2019 - Ottawa, ON, Canada